Skip to main content

Monopar Therapeutics

MNPR
Exchange
Nasdaq
Industry
Pharmaceutical Preparations
SEC CIK
0001645469

In the last 90 days, Monopar Therapeutics insiders filed 0 open-market purchases and 3 sales; 95 institutions reported holding it in 13F filings for Q2 2026, worth $576.1M in total; no superinvestor holds it.

Holders of 5% or more of MNPR

Holders whose latest Schedule 13D or 13G filing reports 5% or more of Monopar Therapeutics, largest stake first. The change is against the holder's previous filing.

Holders of 5% or more of MNPR
HolderLatest formStakeChangeFirst filedLatest filingFiling
Janus Henderson Group PLC13G/A19.50%1.29M shares+0.30 ppfrom 19.20%Jan 8, 20254 filingsNov 14, 2025SEC
Ra Capital Management, L.P.13G/A9.90%667.6K shares0.00 ppfrom 9.90%Feb 14, 20253 filingsFeb 17, 2026SEC
AstraZeneca PLC13G/A7.80%522.7K shares–Feb 6, 20261 filingFeb 6, 2026SEC

Stakes are as of each holder's latest filing. Holders whose last filing was in the old format (before December 18, 2024) have no stake on record and are not listed, and after an acquisition or delisting holders usually stop filing.

13D and 13G filings

16 Schedule 13D and 13G filings on Monopar Therapeutics, newest first, including old-format filings without a stake.

Schedule 13D and 13G filings on MNPR
Filed (ET)FilerFormStakeChangeEvent dateFiling
Aug 12, 20266:26 PM ETSaturn V Capital Management LLCand 1 other13G/A4.70%313.4K shares−0.50 ppfrom 5.20%Below 5%Jun 30, 2026SEC
Aug 12, 202612:05 PM ETAdage Capital Management, L.P.and 2 others13G/A4.76%324.2K shares−1.47 ppfrom 6.23%Below 5%Jun 30, 2026SEC
May 15, 20261:26 PM ETSaturn V Capital Management LLCand 1 other13G5.20%345.6K sharesNewJan 5, 2026SEC
May 13, 20269:10 AM ETAdage Capital Management, L.P.and 2 others13G/A6.23%424.2K shares−3.63 ppfrom 9.86%Mar 31, 2026SEC
Feb 17, 20264:37 PM ETRa Capital Management, L.P.and 3 others13G/A9.90%667.6K shares0.00 ppfrom 9.90%Dec 31, 2025SEC
Feb 6, 20269:54 AM ETAstraZeneca PLCand 1 other13G/A7.80%522.7K shares–Dec 31, 2025SEC
Jan 30, 20262:32 PM ETTactic Pharma LLCand 2 others13D/A4.50%307.4K shares−3.00 ppfrom 7.50%Below 5%Jan 28, 2026SEC
Nov 14, 20254:16 PM ETRa Capital Management, L.P.and 3 others13G/A9.90%742.9K shares0.00 ppfrom 9.90%Sep 30, 2025SEC
Nov 14, 202512:49 PM ETJanus Henderson Group PLCand 1 other13G/A19.50%1.29M shares+0.30 ppfrom 19.20%Sep 30, 2025SEC
Sep 24, 20258:59 PM ETTactic Pharma LLCand 4 others13D/A7.50%506.2K shares–Sep 24, 2025SEC
Aug 14, 202510:58 AM ETJanus Henderson Group PLCand 1 other13G/A19.20%1.17M shares+0.60 ppfrom 18.60%Jun 30, 2025SEC
May 14, 202511:59 AM ETJanus Henderson Group PLCand 1 other13G/A18.60%1.13M shares+1.40 ppfrom 17.20%Mar 31, 2025SEC
Feb 14, 20256:25 PM ETRa Capital Management, L.P.and 3 others13G/A9.90%620.1K shares–Dec 31, 2024SEC
Feb 14, 20254:00 PM ETTang Capital Management LLCand 4 others13G/A0.00%0 shares–Below 5%Dec 31, 2024SEC
Feb 12, 20259:45 AM ETAdage Capital Management, L.P.and 2 others13G9.86%599.2K sharesNewDec 31, 2024SEC
Jan 8, 202511:38 AM ETJanus Henderson Group PLCand 1 other13G/A17.20%1.05M shares–Dec 31, 2024SEC

Form 144: proposed insider sales

1 notice from officers, directors and other affiliates planning to sell Monopar Therapeutics shares, newest first.

Form 144 notices for MNPR
Filed (ET)SellerShares to sellMarket valuePlanned saleBrokerFiling
Sep 24, 20264:40 PM ETChandler RobinsonDirector · Officer29.1K$2.60MSep 24, 202610b5-1Morgan Stanley Smith Barney LLC Executive Financial ServicesSEC